Some leukemic clones might have enhanced resistance to inflammation [115,116,117] or to therapy-induced damage [118,119]; the latter might explain the higher incidence of TP53 and PPM1D mutations in therapy-related AML [119]. This evidence concerns the gene TP53 and acute myeloid leukemia.